NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

Not relevant to current service structure of integrated commissioning boards, and now covered by government guidance on whole systems approach to obesity and the obesity framework.

NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...

The committee noted a recurring theme in the evidence in that overweight and obesity can be complex and multifaceted, and can interact with many areas of a person's life. They agreed on the need to ...

Companies should work with providers and central NHS England teams to begin the research. Planning for a prespecified period for the set-up of the technologies is advised. The following considerations ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

If data collection is expected to end later than planned, the companies should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance ...

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technologies to be ...